Finance

Lists
Why is VRCA down 2,99%?
Dive Deeper
VRCA:NASDAQ
Verrica Pharmaceuticals Inc
USD 4,38
-2,99%
(-0,13) 1D
2 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VRCA...
Open
USD 4,56
High
USD 4,84
Low
USD 4,37
Mkt. cap
75,24 m
Avg. vol.
81,58 k
Volume
0,00
52-wk high
USD 9,82
52-wk low
USD 3,28
EPS
-USD 1,67
Beta
1,60
Shares outstanding
17,18 m
No. of employees
76
Open
USD 4,56
High
USD 4,84
Low
USD 4,37
Mkt. cap
75,24 m
Avg. vol.
81,58 k
Volume
0,00
52-wk high
USD 9,82
52-wk low
USD 3,28
EPS
-USD 1,67
Beta
1,60
Shares outstanding
17,18 m
No. of employees
76
News stories
From web sources and news partners
About Verrica Pharmaceuticals Inc
CEOJayson Rieger
Employees76
Founded2013
HeadquartersWest Chester, Pennsilvanië, Verenigde State van Amerika
SectorPharmaceutical industry
Websiteverrica.com
Analyst ratings
Based on 4 analysts giving stock ratings to VRCA in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for VRCA in the last 3 months.
Highest
Current USD 4,38
USD 20,00 (+356,62%)
Average
USD 13,67 (+212,10%)
Lowest
USD 9,00 (+105,48%)
Analyst
Recommendation
Action
Price target
Projected
Date
Thomas Flaten
Lake Street
Buy
Maintained
USD 9,00
+105,5%
10/01/2026
Serge Belanger
Needham
Hold
Maintained
-
-
08/27/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
USD 12,00
+174%
08/07/2026
Stacy Ku
TD Cowen
Buy
Reiterated
USD 20,00
+356,6%
08/06/2026
Kemp Dolliver
Brookline Capital Markets
Buy
Upgraded
USD 17,00
+288,1%
12/17/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
14,34 m
5,09 m
5,02 m
5,86 m
Cost of goods sold
3,31 m
3,92 m
4,75 m
6,91 m
Cost of revenue
3,31 m
3,92 m
4,75 m
6,91 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,40 m
8,12 m
9,99 m
10,35 m
Operating expense
9,40 m
8,12 m
9,99 m
10,35 m
Total operating expenses
12,72 m
12,04 m
14,74 m
17,26 m
Operating income
1,63 m
-6,95 m
-9,72 m
-11,40 m
Other non operating income
34,00 k
1,76 m
-8,00 k
-3,00 k
EBT including unusual items
-274,00 k
-8,07 m
-9,68 m
-13,15 m
EBT excluding unusual items
-274,00 k
-6,30 m
-9,68 m
-11,46 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-274,00 k
-8,07 m
-9,68 m
-13,15 m
Net profit margin
-1,91%
-158,56%
-192,75%
-224,38%
Earnings per share
0,13
-0,51
-0,45
-0,48
Interest and investment income
159,00 k
205,00 k
201,00 k
111,00 k
Interest expense
-2,09 m
-1,31 m
-160,00 k
-164,00 k
Net interest expenses
-1,94 m
-1,11 m
41,00 k
-53,00 k
Depreciation and amortization charges
-
-
-
-
EBITDA
1,74 m
-6,83 m
-9,60 m
-11,27 m
Gain or loss from assets sale
68,00 k
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme